Development of an AI-Agent for Urological Disease Diagnosis and Treatment

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

About this trial

Urological diseases such as urinary stones, prostate cancer, and bladder cancer are very common and often require highly specialized diagnosis and treatment. Today, the quality of care can vary between doctors, and there are not enough urology specialists to meet patient demand. Artificial intelligence (AI) may help doctors make faster and more consistent decisions.

This study aims to develop and test an AI-powered assistant called "UroAgent" that supports doctors in diagnosing and treating urological diseases. UroAgent is built on a large language model trained specifically for urology and is connected to tools that help it retrieve medical knowledge and analyze images. To build and test UroAgent, the research team will use 1,500 past patient records from 2010-2025 and collect 500 new patient cases for validation, for a total of 2,000 cases. This is an observational study: no patient's medical treatment will be changed because of it. The goal is to create a reliable AI tool that helps improve urological care for patients.

Eligibility criteria

Qualifiers

Diagnosed with a urological disease (e.g., urinary stones, prostate cancer, bladder cancer, and other urological conditions).

Availability of complete clinical information, imaging data, and surgical video required for model development and validation.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

2,000 Participants
are grouped into 1 trial group

Sponsors and collaborators

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Lead sponsor

Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University

Collaborator

Ganzhou City People's Hospital

Collaborator